XTX Topco Ltd Acquires Shares of 13,912 The Cooper Companies, Inc. (NASDAQ:COO)

XTX Topco Ltd acquired a new position in The Cooper Companies, Inc. (NASDAQ:COO) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 13,912 shares of the medical device company’s stock, valued at approximately $1,215,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Treasurer of the State of North Carolina boosted its position in shares of Cooper Companies by 0.9% during the fourth quarter. Treasurer of the State of North Carolina now owns 22,861 shares of the medical device company’s stock valued at $8,652,000 after purchasing an additional 212 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Cooper Companies by 55.3% during the 4th quarter. Hsbc Holdings PLC now owns 87,718 shares of the medical device company’s stock valued at $33,188,000 after buying an additional 31,234 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Cooper Companies in the 1st quarter worth about $2,211,000. Whittier Trust Co. increased its stake in shares of Cooper Companies by 298.9% in the 1st quarter. Whittier Trust Co. now owns 11,940 shares of the medical device company’s stock worth $1,211,000 after acquiring an additional 8,947 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. lifted its position in Cooper Companies by 43.1% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 35,233 shares of the medical device company’s stock valued at $3,076,000 after acquiring an additional 10,616 shares during the period. 24.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

COO has been the topic of a number of recent research reports. Morgan Stanley upped their price objective on shares of Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a report on Tuesday, September 10th. Stifel Nicolaus reaffirmed a “buy” rating and set a $115.00 price objective (up previously from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. Wells Fargo & Company lifted their price objective on Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Finally, Robert W. Baird lifted their price target on Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, August 29th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $115.00.

Insiders Place Their Bets

In other news, COO Daniel G. Mcbride sold 114,992 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the sale, the chief operating officer now owns 44,696 shares of the company’s stock, valued at approximately $4,714,534.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Daniel G. Mcbride sold 114,992 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total value of $12,129,356.16. Following the completion of the sale, the chief operating officer now directly owns 44,696 shares in the company, valued at approximately $4,714,534.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brian G. Andrews sold 24,788 shares of Cooper Companies stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $105.90, for a total value of $2,625,049.20. Following the transaction, the chief financial officer now owns 6,614 shares in the company, valued at $700,422.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 256,373 shares of company stock valued at $27,637,427. Insiders own 2.00% of the company’s stock.

Cooper Companies Stock Performance

Shares of COO stock opened at $110.49 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The company has a 50 day moving average price of $97.54 and a 200-day moving average price of $95.48. The Cooper Companies, Inc. has a 52 week low of $75.93 and a 52 week high of $112.38. The firm has a market capitalization of $22.00 billion, a PE ratio of 64.99, a P/E/G ratio of 2.60 and a beta of 0.98.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.05. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The firm’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.84 EPS. As a group, equities research analysts expect that The Cooper Companies, Inc. will post 3.66 earnings per share for the current year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.